2025 Q3 -tulosraportti
112 päivää sitten
‧1 t 2 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
71 918
Myynti
Määrä
73 348
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 583 | - | - | ||
| 1 077 | - | - | ||
| 23 | - | - | ||
| 791 | - | - | ||
| 47 | - | - |
Ylin
177,3VWAP
Alin
167,9VaihtoMäärä
49 286 733
VWAP
Ylin
177,3Alin
167,9VaihtoMäärä
49 286 733
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 15.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 24.10.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·12 t sittenThe De Novo process is fully transferred in December confirmed by IR from bonesuppport today via email. Now the case is completely de-risked before the report and will probably get a similar upward reaction as the reversed VV in January. For me, everything under 200 is an open goal. Time will tell.
·1 päivä sittenTarget price more than double the current price😳 There's certainly potential in that case😄
·1 päivä sitten · MuokattuAsked CoPilot about the effect of a stronger krona: "Bonesupport – extremely currency-resistant thanks to USA dominance and high gross margin 1. Volumes and growth Bonesupport is growing explosively, especially in the USA: Q4 2024: +59 % in North America Full year 2024: +63 % in North America, +22 % in Europe/rest of the world Q3 2025: +28 % in USA (+40 % in constant currency) This is not a company that loses volumes – quite the opposite. Growth is so strong that currency headwinds are barely visible in the top-line. 2. Gross margins that absorb currency effects Bonesupport has gross margins over 90 % . This means that: currency changes affect margins much less than in traditional industry the company can raise prices without losing volumes the cost base is relatively small in relation to sales This is one of the most currency-insensitive business models on the Stockholm Stock Exchange. 3. Competitive situation According to management, Bonesupport is ”far ahead of competing alternatives” in both technology and clinical evidence . This is also evident in: rapid adoption of Cerament G upcoming expansion with Cerament V (FDA application Q1 2025) new indications (spine) on the way This is a company that gains market shares, not loses them. 4. Conclusion for Bonesupport A stronger krona is in principle irrelevant for volumes. Growth is driven by the USA, margins are sky-high and the competitive advantage is structural. The only thing affected is reported SEK‑profits – not the business's fundamentals." Do you agree?·1 päivä sittenI haven't dug into it, but it's about many different aspects. One thing it says is that they can raise prices without losing market share, e.g. Personally, I always think that I might get a few fewer kronor, but the kronor are worth more and I haven't lost anything! The problem is when a company has large costs in kronor and cannot rationalize or raise the price.
·6.2.A P/E of over 100. Rising costs of 33%. Every krone sold costs 50% in expenses. It needs to be halved in share price and then it's still expensive.·2 päivää sittenAccording to the Q3 report, the profit LTM (Last Twevle Months) was 2.28, and then I don't calculate the P/E to be over a hundred but around 75. We'll see where the profit lands after Q4. The only problem I worry about is that the largest sales are in the USA and there the Trump mafia is raging, and then you never know what will happen. My hope (and nothing else) is that the stock price turns up here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
112 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sittenThe De Novo process is fully transferred in December confirmed by IR from bonesuppport today via email. Now the case is completely de-risked before the report and will probably get a similar upward reaction as the reversed VV in January. For me, everything under 200 is an open goal. Time will tell.
- ·1 päivä sittenTarget price more than double the current price😳 There's certainly potential in that case😄
- ·1 päivä sitten · MuokattuAsked CoPilot about the effect of a stronger krona: "Bonesupport – extremely currency-resistant thanks to USA dominance and high gross margin 1. Volumes and growth Bonesupport is growing explosively, especially in the USA: Q4 2024: +59 % in North America Full year 2024: +63 % in North America, +22 % in Europe/rest of the world Q3 2025: +28 % in USA (+40 % in constant currency) This is not a company that loses volumes – quite the opposite. Growth is so strong that currency headwinds are barely visible in the top-line. 2. Gross margins that absorb currency effects Bonesupport has gross margins over 90 % . This means that: currency changes affect margins much less than in traditional industry the company can raise prices without losing volumes the cost base is relatively small in relation to sales This is one of the most currency-insensitive business models on the Stockholm Stock Exchange. 3. Competitive situation According to management, Bonesupport is ”far ahead of competing alternatives” in both technology and clinical evidence . This is also evident in: rapid adoption of Cerament G upcoming expansion with Cerament V (FDA application Q1 2025) new indications (spine) on the way This is a company that gains market shares, not loses them. 4. Conclusion for Bonesupport A stronger krona is in principle irrelevant for volumes. Growth is driven by the USA, margins are sky-high and the competitive advantage is structural. The only thing affected is reported SEK‑profits – not the business's fundamentals." Do you agree?·1 päivä sittenI haven't dug into it, but it's about many different aspects. One thing it says is that they can raise prices without losing market share, e.g. Personally, I always think that I might get a few fewer kronor, but the kronor are worth more and I haven't lost anything! The problem is when a company has large costs in kronor and cannot rationalize or raise the price.
- ·6.2.A P/E of over 100. Rising costs of 33%. Every krone sold costs 50% in expenses. It needs to be halved in share price and then it's still expensive.·2 päivää sittenAccording to the Q3 report, the profit LTM (Last Twevle Months) was 2.28, and then I don't calculate the P/E to be over a hundred but around 75. We'll see where the profit lands after Q4. The only problem I worry about is that the largest sales are in the USA and there the Trump mafia is raging, and then you never know what will happen. My hope (and nothing else) is that the stock price turns up here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
71 918
Myynti
Määrä
73 348
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 583 | - | - | ||
| 1 077 | - | - | ||
| 23 | - | - | ||
| 791 | - | - | ||
| 47 | - | - |
Ylin
177,3VWAP
Alin
167,9VaihtoMäärä
49 286 733
VWAP
Ylin
177,3Alin
167,9VaihtoMäärä
49 286 733
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 15.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 24.10.2024 |
2025 Q3 -tulosraportti
112 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 15.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 24.10.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sittenThe De Novo process is fully transferred in December confirmed by IR from bonesuppport today via email. Now the case is completely de-risked before the report and will probably get a similar upward reaction as the reversed VV in January. For me, everything under 200 is an open goal. Time will tell.
- ·1 päivä sittenTarget price more than double the current price😳 There's certainly potential in that case😄
- ·1 päivä sitten · MuokattuAsked CoPilot about the effect of a stronger krona: "Bonesupport – extremely currency-resistant thanks to USA dominance and high gross margin 1. Volumes and growth Bonesupport is growing explosively, especially in the USA: Q4 2024: +59 % in North America Full year 2024: +63 % in North America, +22 % in Europe/rest of the world Q3 2025: +28 % in USA (+40 % in constant currency) This is not a company that loses volumes – quite the opposite. Growth is so strong that currency headwinds are barely visible in the top-line. 2. Gross margins that absorb currency effects Bonesupport has gross margins over 90 % . This means that: currency changes affect margins much less than in traditional industry the company can raise prices without losing volumes the cost base is relatively small in relation to sales This is one of the most currency-insensitive business models on the Stockholm Stock Exchange. 3. Competitive situation According to management, Bonesupport is ”far ahead of competing alternatives” in both technology and clinical evidence . This is also evident in: rapid adoption of Cerament G upcoming expansion with Cerament V (FDA application Q1 2025) new indications (spine) on the way This is a company that gains market shares, not loses them. 4. Conclusion for Bonesupport A stronger krona is in principle irrelevant for volumes. Growth is driven by the USA, margins are sky-high and the competitive advantage is structural. The only thing affected is reported SEK‑profits – not the business's fundamentals." Do you agree?·1 päivä sittenI haven't dug into it, but it's about many different aspects. One thing it says is that they can raise prices without losing market share, e.g. Personally, I always think that I might get a few fewer kronor, but the kronor are worth more and I haven't lost anything! The problem is when a company has large costs in kronor and cannot rationalize or raise the price.
- ·6.2.A P/E of over 100. Rising costs of 33%. Every krone sold costs 50% in expenses. It needs to be halved in share price and then it's still expensive.·2 päivää sittenAccording to the Q3 report, the profit LTM (Last Twevle Months) was 2.28, and then I don't calculate the P/E to be over a hundred but around 75. We'll see where the profit lands after Q4. The only problem I worry about is that the largest sales are in the USA and there the Trump mafia is raging, and then you never know what will happen. My hope (and nothing else) is that the stock price turns up here.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
71 918
Myynti
Määrä
73 348
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 583 | - | - | ||
| 1 077 | - | - | ||
| 23 | - | - | ||
| 791 | - | - | ||
| 47 | - | - |
Ylin
177,3VWAP
Alin
167,9VaihtoMäärä
49 286 733
VWAP
Ylin
177,3Alin
167,9VaihtoMäärä
49 286 733
Välittäjätilasto
Dataa ei löytynyt